H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?
Critically ill patients routinely receive H(2) antagonists for stress ulcer prophylaxis while at risk for gastrointestinal bleeding. In these patients it is often difficult to assess accurately the cause of adverse effects such as thrombocytopenia. We evaluate the literature to better define thrombocytopenia related to H(2) antagonist administration and discuss mechanism, potential as a risk factor and case reports describing the severity and duration of thrombocytopenia.
Wade
Emily E
EE
Department of Pharmacy, University of Pittsburgh Medical Center, 304 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Rebuck
Jill A
JA
Healey
Mark A
MA
Rogers
Frederick B
FB
D002927:Cimetidine / Q000009:adverse effects; D003422:Critical Care; D015738:Famotidine / Q000009:adverse effects; D006635:Histamine H2 Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D010437:Peptic Ulcer / Q000517:prevention & control*; D011899:Ranitidine / Q000009:adverse effects; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced*
D006635:Histamine H2 Antagonists; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine